Antibodies to amyloid beta

Patent metadata

Field	Value
Publication number	US-12344664-B2
Application number	US-202418604668-A
Country	US
Kind code	B2
Filing date	Mar 14, 2024
Priority date	Oct 15, 2012
Publication date	Jul 1, 2025
Grant date	Jul 1, 2025

Abstract

Antibody for human amyloid beta. Antibody selectively binds human amyloid beta 42 peptide over human amyloid beta 40 peptide. Antibodies specific for amyloid beta 42 as therapeutic agents for binding amyloid beta 42 peptide and treating conditions associated with amyloidosis, such as Alzheimer's disease.

First claim

What is claimed is:

1. An isolated antibody molecule that is selective for binding human amyloid beta 1-42 peptide (Aβ1-42) over human amyloid beta 1-40 peptide (Aβ1-40); wherein the antibody molecule comprises:
(i) a VH domain comprising the following HCDRs:
HCDR1 SEQ ID NO: 525,
HCDR2 SEQ ID NO: 526, and
HCDR3 SEQ ID NO: 527, and
(ii) a VL domain comprising the following LCDRs:
LCDR1 SEQ ID NO: 534,
LCDR2 SEQ ID NO: 535, and
LCDR3 SEQ ID NO: 536;
and wherein the VL domain has a threonine at the amino acid position corresponding to position 80 of SEQ ID NO: 407.

2. The antibody molecule according to claim 1 , wherein the VH domain has an arginine at the amino acid position corresponding to position 43 of SEQ ID NO: 398.

3. The antibody molecule according to claim 1 , wherein the antibody molecule is capable of binding soluble monomeric AB1-42 with a dissociation constant (KD) of 500 pM.

4. The antibody molecule according to claim 1 , wherein the antibody molecule is capable of binding low n oligomeric (up to and including pentamer) human AB1-42 with a dissociation constant (KD) of 500 pM or less.

5. The antibody molecule according to claim 1 , wherein the antibody either does not bind Aβ1-40 or binds Aβ1-40 with a dissociation constant (K D ) greater than 1 mM.

6. The antibody molecule according to claim 1 , wherein the antibody molecule binds amyloid beta 17-42 peptide (Aβ17-42) and amyloid beta 29-42 peptide (Aβ29-42).

7. The antibody molecule according to claim 1 , wherein the antibody molecule binds 3-pyro-42 amyloid beta peptide and 11-pyro-42 amyloid beta peptide.

8. The antibody molecule according to claim 1 , wherein the antibody molecule binds amyloid beta 1-43 peptide (Aβ1-43).

9. The antibody molecule according to claim 1 , wherein the VH domain comprises heavy chain framework regions FW1, FW2, FW3 and FW4, wherein the amino acid sequences of the heavy chain framework regions are
FW1 SEQ ID NO: 402
FW2 SEQ ID NO: 403
FW3 SEQ ID NO: 404, and
FW4 SEQ ID NO: 405
or wherein FW1 comprises SEQ ID NO: 402 with one or more amino acid substitutions, wherein the one or more substitutions in FW1 are selected from:

a) amino acid 26 of SEQ ID NO: 402 is substituted by glycine, serine, valine, alanine, asparagine, threonine, or histidine;
b) amino acid 27 of SEQ ID NO: 402 is substituted by phenylalanine, serine, tyrosine, glutamic acid, aspartic acid, or proline;
c) amino acid 28 of SEQ ID NO: 402 is substituted by glutamine, histidine, valine, glutamic acid, threonine, alanine, serine, aspartic acid, methionine, or proline;
d) amino acid 29 of SEQ ID NO: 402 is substituted by isoleucine, tyrosine, serine, leucine, or tryptophan; and
e) amino acid 30 of SEQ ID NO: 402 is substituted by serine, threonine, glutamine, lysine, histidine, arginine, glycine, proline, glutamic acid, alanine, or aspartic acid;
or a combination thereof.

10. The antibody molecule according to claim 1 , wherein the VL domain comprises light chain framework regions FW1, FW2, FW3 and FW4, wherein the amino acid sequences of the light chain framework regions are
FW1 SEQ ID NO: 411
FW2 SEQ ID NO: 412
FW3 SEQ ID NO: 413, and
FW4 SEQ ID NO: 414.

11. The antibody molecule according to claim 1 , wherein the antibody molecule is a monoclonal antibody.

12. The antibody molecule according to claim 1 , wherein the antibody molecule is a Fab or an scFv.

13. The antibody molecule according to claim 1 , wherein the antibody molecule is a human IgG.

14. The antibody molecule according to claim 1 , wherein the antibody molecule is a human IgG1 or human IgG2.

15. The antibody molecule according to claim 1 , wherein the antibody molecule is a human IgG1-TM, IgG1-YTE or IgG1-TM-YTE.

16. A composition comprising an antibody molecule according to claim 1 , and a pharmaceutically acceptable excipient.

17. A method of treating a human or animal subject, comprising administering to the subject an antibody molecule according to claim 1 .

18. A method of reducing amyloidosis, treating Alzheimer's disease, improving cognition, or reducing cognitive decline in an individual with Alzheimer's disease or Down's syndrome, and/or treating macular degeneration in an individual, comprising administering to the individual an antibody molecule according to claim 1 .

19. A method of treating a human or animal subject, comprising administering to the subject a composition according to claim 16 .

20. A method of reducing amyloidosis, treating Alzheimer's disease, improving cognition, or reducing cognitive decline in an individual with Alzheimer's disease or Down's syndrome, and/or treating macular degeneration in an individual, comprising administering to the individual a composition according to claim 16 .

Assignees

• Medimmune Ltd

Inventors

• Groves Maria
• Gustavsson Suzanne
• Höglund Kina
• Lloyd Chris
• Nickson Adrian
• Niva Camilla
• Simon Sylvia
• Lowne David
• Welsh Fraser
• Freskgärd Per-Ola

Classifications

• C07K2317/60

  characterized by non-natural combinations of immunoglobulin fragments · CPC title

• C07K2317/567

  Framework region [FR] · CPC title

• C07K2317/515

  Complete light chain, i.e. VL + CL · CPC title

• C07K2317/51

  Complete heavy chain or Fd fragment, i.e. VH + CH1 · CPC title

• A61K2039/505

  comprising antibodies · CPC title